{
    "nct_id": "NCT03126110",
    "official_title": "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies",
    "inclusion_criteria": "* Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.\n* Phase 1: Subjects with advanced or metastatic solid tumors.\n* Phase 1: Subjects who have disease progression after treatment with available therapies.\n* Phase 2: Subjects with advanced or metastatic cervical cancer, gastric cancer (including stomach, esophageal, and GEJ), SCCHN, PD-1 refractory SCCHN and PD-1/PD-L1 relapsed melanoma.\n* Presence of measurable disease based on RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Laboratory and medical history parameters not within the Protocol-defined range\n* Prior treatment with any tumor necrosis factor super family agonist.\n* Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.\n* Has not recovered to â‰¤ Grade 1 from toxic effects of prior therapy.\n* Active autoimmune disease.\n* Known active central nervous system metastases and/or carcinomatous meningitis.\n* Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.\n* Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.\n* Known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies).",
    "miscellaneous_criteria": ""
}